Ignite Creation Date:
2025-12-24 @ 4:55 PM
Ignite Modification Date:
2025-12-27 @ 9:29 PM
Study NCT ID:
NCT00857350
Status:
COMPLETED
Last Update Posted:
2013-07-22
First Post:
2009-03-04
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment
Sponsor:
Yale University
Organization:
Study Overview
Official Title:
The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment
Status:
COMPLETED
Status Verified Date:
2013-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
HIV drug resistance presents a significant public heath problem. This proposal is designed to explore the association between ongoing illicit drug use and the prevalence of HIV drug resistance among HIV+ opioid dependent patients receiving opioid agonist treatment with the following hypotheses:
1. Hypothesis 1: The prevalence of HIV drug resistance will range between 10% and 30%.
2. Hypothesis 2: Patients with evidence of ongoing illicit drug use will be more likely to have HIV drug resistance.
1. Hypothesis 1: The prevalence of HIV drug resistance will range between 10% and 30%.
2. Hypothesis 2: Patients with evidence of ongoing illicit drug use will be more likely to have HIV drug resistance.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: